Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of mannoglucuronic acid oligosaccharides and derivatives thereof in the preparation of medicines for treating and/or preventing hcmv

A technology of glucuronic acid and uronic acid oligosaccharides, which is applied in the application field of preparing medicines for treating and/or preventing HCMV, and achieves the effect of less toxic and side effects

Active Publication Date: 2021-09-17
ZHEJIANG HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, there is no application of mannoglucuronide oligosaccharides in the preparation of drugs for preventing and / or treating HCMV.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mannoglucuronic acid oligosaccharides and derivatives thereof in the preparation of medicines for treating and/or preventing hcmv
  • Application of mannoglucuronic acid oligosaccharides and derivatives thereof in the preparation of medicines for treating and/or preventing hcmv
  • Application of mannoglucuronic acid oligosaccharides and derivatives thereof in the preparation of medicines for treating and/or preventing hcmv

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0116] The preparation of embodiment 1 mannoglucuronic acid oligosaccharides

[0117] Extract the dried kelp with 30 times the mass of distilled water at 100°C for 3 hours, filter the extract, concentrate, add ethanol to a final concentration of 75% to precipitate, let it stand for 12 hours, collect the precipitate, sink to the point of vacuum drying to obtain laminarin . Dissolve the laminarin sample in a sulfuric acid solution with a mass concentration of 4% (the ratio of solid to liquid is 60mg / mL), heat and reflux for 5 hours, neutralize with barium hydroxide to PH=6-7, centrifuge, and concentrate the supernatant to the original One-fifth of the volume, the concentrated solution is subjected to active carbon column chromatography, firstly equilibrated with distilled water, and then eluted with a gradient of 50%-90% ethanol, and the 50%-90% ethanol eluate is concentrated to one-fifth of the original volume 1. Ethanol was evaporated, and directly applied to Bio-gel P4 colum...

Embodiment 2

[0124] The preparation of embodiment 2 sulfated mannoglucuronide oligosaccharides

[0125] The mannoglucuronide oligosaccharide monomers GM2, GM4, GM6 (mannose glucuronide disaccharide, tetrasaccharide, hexasaccharide) obtained in Example 1 were dissolved in DMF (0.05g / ml) under nitrogen protection conditions, Then add sulfur trioxide pyridinium salts of different quality, and stir at room temperature for 24 hours. The reaction solution was poured into 4 times ice-distilled water, neutralized, and desalted with Sephadex G10. The eluate was concentrated, separated and purified on Bio-gel P4 to obtain GlcAMan (SO 3 h) 1-3 , GlcAMan (SO 3 h) 3-5 , GlcA 2 man 2 (SO 3 h) 8-11 , GlcA 2 man 2 (SO 3 h) 5-9 , GlcA 2 man 2 (SO 3 h) 1-5 , GlcA 3 man 3 (SO 3 h) 4-10 , GlcA 3 man 3 (SO 3 h) 1-6 , GlcA 3 man 3 (SO 3 h) 8-15 .

Embodiment 3

[0126]Example 3 Effects of Mannoglucuronide Oligosaccharides and Derivatives Treated Alone on the Proliferation Activity of WI-38 Cells

[0127] The cell viability was detected by the MTT method as follows: PD30 human embryonic lung fibroblast WI-38 cells were seeded in 96-well cell culture plates at 3000 cells per well, and after 24 hours of culture, different concentrations of mannoglucuronide oligosaccharides were added. Three parallel wells were set up for each concentration, and a blank control group without drug and a cell-free lysis control group were set up. After culturing for 48 hours, add 20 μl MTT (5 mg / ml, prepared with serum-free DMEM culture solution) to each well, at 37°C, 5% CO 2 Incubate under the conditions for 4 hours, carefully suck up the liquid in the wells, add 150 μl DMSO to each well, and shake gently on the shaker for 10 minutes to fully dissolve the crystals, then measure the light absorbance at 570nm, and calculate the relative cell viability. The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of mannoglucuronic acid oligosaccharides and derivatives thereof in the preparation of medicines for treating and / or preventing HCMV. Mannoglucuronic acid oligosaccharide is the main chain of mannoglucuronic acid oligosaccharide formed by alternating connection of 2-linked mannose and 4-linked glucuronic acid or its salt. Experiments show that mannoglucuronic acid oligosaccharide Treatment of HCMV in vitro host cells-human embryonic lung diploid fibroblasts WI-38 alone has no obvious cytotoxicity at a concentration of 10-1000 μg / ml, and can significantly improve the cytopathic effect caused by HCMV-infected cells, and can effectively inhibit The expression of HCMV immediate early protein IE1 / 2 and early protein UL44 in WI‑38 inhibits the amplification of HCMV gene UL‑123, thus having the application prospect of preparing anti-HCMV drugs for prevention and / or treatment.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the application of mannoglucuronic acid oligosaccharides and derivatives thereof in the preparation of medicines for treating and / or preventing HCMV. Background technique [0002] Human cytomegalovirus (HCMV) belongs to the herpesvirus β subfamily and is commonly infected in the population. In healthy individuals, the primary infection of HCMV is mostly recessive infection. After the infection is relieved, the virus cannot be completely cleared. But long-term latent in the body. Infection of HCMV has little effect on normal immunocompetent population, but it is fatal in immunocompromised persons, such as AIDS patients and organ transplant patients; in pregnant women, due to changes in endocrine and metabolic functions, it is easy to activate the HCMV in the incubation period causes HCMV recurrent infection and is the main pathogen causing congenital diseases in newborns, causing icteric ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7016A61K31/702A61K31/736A61P31/22
CPCA61K31/7016A61K31/702A61K31/736A61P31/22
Inventor 王三应毛根祥严静金维华暴一众张婧徐小刚孙川代继桓
Owner ZHEJIANG HOSPITAL